Neurocrine Expands Rare Disease Portfolio with $2.9B Soleno Buy
Neurocrine will buy Soleno for $2.9B, adding VYKAT XR, the first drug for extreme hunger in rare Prader-Willi syndrome.
/ 4 items
#SLNO↓
Raymond James Starts Coverage of Aardvark Therapeutics With Strong Buy Rating
Raymond James initiates Aardvark Therapeutics with a Strong Buy and a $47 price target, highlighting strong Phase 2 data for ARD-101 and unmet needs in hyperphagia treatment.
Acadia Pharmaceuticals Shares Fall as ACP-101 Trial Misses Primary Endpoint
Acadia's experimental drug, ACP-101 (intranasal carbetocin), designed to treat extreme hunger (hyperphagia) in Prader-Willi syndrome patients, did not meet its main goal in the recent Phase 3 trial.
Soleno Therapeutics: Patient Death and Vykat XR Scrutiny
Soleno's stock dipped after a PWS patient died. Company & doctor say death (pulmonary embolus) was unrelated to VYKAT XR, citing patient's co-morbidities & PWS risks.